Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 37311011 approvals

Xcell Therapeutics Inc.

Official website

Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.

As of 2026-10-10, Xcell Therapeutics Inc. has 11 Korean MFDS device approvals, 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2015, Xcell Therapeutics listed on KOSDAQ in 2024 as a cell culture media company. It has localized a series of cell and gene therapy media under the CellCor™ brand, including CD MSC (launched 2020), Kera SF (2021), EXO CD and Kera CD (April 2023), DPC CD (December 2023), and MSC CD AOF (May 2023), as the global cell therapy market is projected to grow at a 15.3% CAGR to USD 30.6 billion (about KRW 42.6 trillion) by 2034. In 2025 it signed a series of agreements: with Becton Dickinson for domestic distribution rights to flow cytometry equipment, with China's Bloomage Biotechnology for exclusive supply of T-cell and NK-cell media, with Japan's Peptide Growth for synthetic peptide growth factor supply, and with Belgium's Trince for exclusive domestic supply of transfection solutions.

Products & technology

  • CellCor™ CD MSCMesenchymal stem cell culture media
  • CellCor™ MSC CD AOFAnimal-origin-free stem cell culture media
  • CellCor™ Kera SFSerum-free keratinocyte culture media
  • CellCor™ DPC CDDermal papilla cell culture media for hair-loss cell therapy
  • CellCor™ EXO CDCulture media specialized for exosome production
  • CellCor™ Kera CDAnimal-origin-free keratinocyte culture media

Regulatory approvals

data.go.kr

11 Korean MFDS device approvals · 2020–2025

  • MFDSFlow cytometry2025-05-27
    Product approval · Class 1체외 수신 25-1077 호
  • MFDSTool for specimensRevoked2021-09-16
    Product approval · Class 1제신 21-1265 호
  • MFDSSpecimen transport mediaRevoked2020-11-09
    Product approval · Class 1체외 제신 20-1639 호
  • MFDSSpecimen transport mediaRevoked2020-10-27
    Product approval · Class 1체외 제신 20-1587 호
  • MFDSSpecimen transport mediaRevoked2020-10-15
    Product approval · Class 1체외 제신 20-1536 호
  • MFDSSpecimen transport media2020-09-23
    Product approval · Class 1체외 제신 20-1456 호
  • MFDSSpecimen transport media2020-09-09
    Product approval · Class 1체외 제신 20-1383 호
  • MFDSSpecimen transport media2020-09-09
    Product approval · Class 1체외 제신 20-1382 호
  • MFDSSpecimen transport media2020-08-31
    Product approval · Class 1체외 제신 20-1320 호
  • MFDSSpecimen transport media2020-06-02
    Product approval · Class 1체외 제신 20-789 호
  • MFDSSpecimen transport mediaRevoked2020-05-27
    Product approval · Class 1체외 제신 20-723 호

R&D and key agreements

Source: DART corporate disclosure

CellCor™ MSC CD AOF(Upgrade.ver) · 세포치료제 생산공정용 배지 · 연구개발중(2025.01~2026.06 예정) · Developing a culture medium composition allowing direct human injection after culture without a washing step

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 15 more patents

AI reads

MAA server logs · IP-verified
38
Times AI engines pulled Xcell Therapeutics Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

37
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

7
live 0
Last 7 days
29
live 1
Last 30 days
38
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot27
  • GoogleGoogleOther5
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Xcell Therapeutics Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

PCL. Inc3 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

Ensol Biosciences Inc.2 shared

Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).

Median Diagnostics Inc.2 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

RollingStone Co., Ltd.2 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

BIONEERCORPORATION2 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

SD BIOSENSOR INC.2 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

HLB Life Science CO.,LTD.1 shared

Founded in 1998 and listed on KOSDAQ in 2008, HLB Life Science operates four business divisions: medicare, bio-development, medical devices, and energy.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Sugentech, Inc.1 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

SEEGENE, INC.1 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition